Nina V. Wressnigg
Vaccine R&D
Vienna, Austria
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.
Journal: Nature medicine
Published: July 07, 2025
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.
Journal: The Lancet. Infectious diseases
Published: May 16, 2024
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.
Journal: The Lancet. Infectious diseases
Published: March 19, 2024
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.
Journal: Journal of travel medicine
Published: October 12, 2023
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.
Journal: The Lancet. Infectious diseases
Published: September 20, 2023
Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults.
Journal: The Lancet. Infectious diseases
Published: January 16, 2023
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: October 25, 2022
A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccine.
Journal: Journal of travel medicine
Published: July 22, 2022
Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera.
Journal: JCI insight
Published: April 15, 2022
Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial.
Journal: Critical care (London, England)
Published: November 11, 2019
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: October 01, 2019
A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice.
Journal: Archives of virology
Published: March 06, 2015
Last Updated: 09/26/2026